Array Biopharma hires Dr Howard Holden as VP regulatory affairs

Dr Howard Holden has joined Array Biopharma as VP of regulatory affairs and quality assurance.

Dr Holden will handle regulatory proceedings as the US biopharma aims to bring to market its pipeline of small molecule drugs to treat cancer and inflammatory diseases.

He has spent over 25 years in the pharma and biotech industry, including most recently 7 years at Nereus Pharmaceuticals as senior VP regulatory affairs and compliance.

Previously, Dr Holden was VP of regulatory affairs and compliance at Stressgen Biotechnologies and Ligand Pharmaceuticals; senior director at Parke-Davis/Warner-Lambert, director at Centocor and senior investigator at the US National Cancer Institute.

"Howard's lifetime of regulatory experience will help Array navigate the FDA approval path for our proprietary programmes," said Kyle Lefkoff, executive chair, Array BioPharma.

"He will make an immediate contribution as we move our pipeline into registration studies, and we're all excited to have Howard on the Array team."